Physician profile
Sarah T Wright
NPI 1275034209
$6,888.78
in general payments reported to CMS, 2019-2025
49 companies · $1,523 in 2025
The $1,523 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,109 · 2022: $1,468 · 2023: $1,225 · 2024: $1,563 · 2025: $1,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,311.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,052.88 | 2021-2025 | |
| Novo Nordisk INC | $760.32 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $735.91 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $586.10 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $502.98 | 2021-2025 | |
| Amgen INC. | $330.64 | 2021-2025 | Prolia, Evenity, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $258.01 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.14 | 2021-2025 | Jardiance |
| Viiv Healthcare Company | $213.67 | 2023-2025 | Dovato, Rukobia |
| Biohaven Pharmaceuticals, INC. | $195.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $192.60 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $187.70 | 2021-2025 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $137.63 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $130.86 | 2022-2024 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $93.48 | 2022-2024 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.